Myeloproliferative neoplasms (MPNs) are clonal disorders of aging hematopoietic stem cells and early myeloid progenitors. A somatic activating point mutation in the Jak2 tyrosine kinase (Jak2 V617F ) is the most prevalent genetic aberration in BCR-ABL-negative MPNs. Janus kinases (JAKs) are essential for cytokine-induced intracellular signaling and their inactivation leads to impaired immune cell function. Therapeutic inhibition of JAKs in MPN patients causes decreased number and function of immune cells, 1, 2 and therefore may contribute to increased incidence and re-activation of viral infections.
3 Jak2 V617F mutation is detectable in hematopoietic stem and progenitor cells of MPN patients and has also been described in lymphoid progenitors and more differentiated lymphocytes, [4] [5] [6] [7] including Jak2 V617F mutated T-cells. 4 However, depending on the allelic burden, incidence and clone size, the number of Jak2 V617F mutated T-cells may have been underestimated, and it is currently unclear whether both CD4 + and CD8 + T-lymphocytes may be equally affected by the Jak2 V617F mutation. Therefore, we aimed to assess for the frequency of Jak2 V617F mutation in CD3 + T-lymphocytes of patients with high-allelicburden MPNs and investigated the impact of Jak2 V617F mutation on T-cell function in vivo. A model with T-cell-specific Jak2 V617F expression was analyzed under physiological conditions and upon infection with an intracellular pathogen.
To address the frequency of JAK2 V617F mutations in human T-cells, we selected 13 MPN patients from our institutional database diagnosed with Jak2 V617F -positive polycythemia vera, essential thrombocythemia or myelofibrosis (PMF) that exhibited an allelic burden of more than 50% in peripheral blood granulocytes. CD3 + T-cells and granulocytes were FACS-sorted and analyzed for quantitative expression of Jak2 V617F (Figure 1a ). Six out of thirteen patients tested positive for Jak2 V617F in sorted CD3 + cells, with an allelic burden between 2 and 47.8% within the T-cell compartment (Figure 1a ). When analyzing sorted CD3/CD4 and CD3/CD8 T-cells of three additional patients with a high allelic burden separately, Jak2 V617F burden was comparable in both T-cell subsets (Figure 1b) . These data suggest that JAK2 V617F mutations may be more frequent in patients with high allelic burden, especially in those diagnosed with polycythemia vera and PMF. The presence of JAK2 V617F in both CD4 + and CD8 + T-cells is consistent with a genetic event that arises at the stem-and progenitor-cell level.
To explore the T-cell-specific function of Jak2 V617F mutated clones in vivo, we crossed C57BL/6 Jak2 V617F 8 with CD4-Cre mice. The resulting CD4-Cre Jak2 V617F mice (henceforth designated as Jak2 +/VF ) exhibited heterozygous expression of Jak2 V617F in CD4 + and CD8 + T-cells but not in the myeloid lineage (for example, granulocytes, Figure 1c ). Those animals were compared to wildtype and Cre-negative littermate controls (henceforth designated as Jak2 +/+ ). Activation of Jak2 V617F in T-cells could potentially lead to alteration of thymic development and composition of T-cell subsets. However, T-cell development in the thymus (Supplementary Figure 1a T-cells are activated in listeriosis and, in particular, CD8 + T-cells, which peak at day 7 post infection (p.i.), are pivotal for final elimination of the pathogen around day 14 p.i. 9 The cytokines, tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte-macropahge colony-stimulating factor (GM-CSF) and interferon-γ (IFN-γ) are critically important for control and survival of listeriosis. 10 In our model, infection with Lm resulted in an increase of CD4 + and CD8 + T-cells in spleens of Jak2 +/VF and Jak2 +/+ control mice, which was slightly pronounced in Jak2 +/VF mice (Supplementary Figure 2a) . Importantly, Lm-specific T-cell responses were greatly augmented in Jak2 Consistent with elevated G-CSF and GM-CSF production, listeriosis induced a significantly stronger increase of neutrophils in the spleen, blood, liver and lung of Jak2 +/VF mice (Figure 2c ). In mice, neutrophils only marginally contribute to the control of Lm.
12 Therefore, the generalized increase of neutrophils does not necessarily contribute to an improved pathogen control but may rather be the consequence of increased paracrine cytokine stimulation. Abundance of all other major leukocyte populations was comparable to non-infected and infected Jak2 +/VF mice and Jak2 +/+ littermate controls in the spleen and blood (Supplementary Figure 2b) . Jak2 V617F promotes chronic inflammation through induction of pro-inflammatory cytokines, which contribute to constitutional symptoms in MPN patients. At present, it is unclear whether an increased activation of Jak2 in affected lymphocytes may add to disease progression and inflammation in MPN. Production and secretion of cytokines by Jak2 V617F -positive cells may impact expansion of the erythroid lineage as well as proliferation of malignant and non-malignant progenitors. 13 To investigate the potential paracrine effects of Jak2 +/VF T-cell-mediated cytokine secretion, we assessed for red blood cell numbers in the spleen. , CD8 + T-cells and granulocytes, respectively, was analyzed by PCR according to previously published protocols. 8 (d) Experimental design of Listeria infection: Jak2 +/VF and Jak2 +/+ mice were infected with Lm and were analyzed at day 7 p.i.
Lm infection increased erythroid progenitor numbers in both strains compared to non-infected controls. This increase, however, appeared sevenfold higher in Jak2 +/VF mice compared to Jak2 +/+ littermate controls (Figure 2d, Supplementary Figure 2c) . Consistently, serum erythropoietin concentration was suppressed in Jak2 +/VF mice following infection on day 7 (Figure 2e ). To further analyze the effect of T-cell-specific Jak2 V617F in a pathogen-independent context, we stimulated isolated naive CD4 + and CD8 + T-cells with anti-CD3/CD28 in vitro. As illustrated in Supplementary Figures 3a and b , both IFN-γ and TNF production and proliferation of Jak2 +/VF CD4 + and CD8 + T-cells were significantly increased. In addition, we treated mice with the plant lectin Concanavalin A (ConA), which activates T-cells via crosslinking of the CD3/T-cell receptor complex and other immune cells by binding to receptors containing mannose carbohydrates. ConA stimulation resulted in a significantly stronger increase of Jak2 +/VF CD4 + and CD8 + T-cells (Supplementary Figure 4a) , increased production of IFN-γ, TNF and GM-CSF by Jak2 +/VF CD4 + and CD8 + T-cells ( Supplementary  Figure 4b) , and augmented incorporation of bromodeoxyuridine in proliferating Jak2 +/VF CD4 + and CD8 + T-cells (Supplementary  Figure 4c) . Functionally important ConA stimulation also caused a significantly stronger increase of neutrophils and erythroblasts in Jak2 +/VF mice ( Supplementary Figures 4d and e) . As outlined above, Jak2 +/VF mice did not develop any clinical signs of an inflammatory syndrome in the absence of an infectious stimulus. Both uninfected Jak2 +/VF mice and Jak2 +/+ littermate controls revealed minor numbers of TNF-, GM-CSF-and IFN-γ-producing CD4 + and CD8 + T-cells (Figure 2c ), low levels of erythropoietin in serum (Figure 2j ) and normal histology of the liver, spleen and lung (not shown). Thus, activating stimuli are probably required to induce the augmented inflammatory phenotype in Jak2 V617F -mutated CD4 + and CD8 + T-cells. In conclusion, almost 50% (9/16) of patients with high-allelicburden Jak2 V617 MPN that were investigated in our study had in addition to granulocytes Jak2 V617F -mutated T-cell clones, and the mutation affected both CD4 + and CD8 + T-cells. Due to the limited number of patients in this study and a high variability of therapeutic approaches (including hydroxyurea, JAK-inhibitor treatment and irradiation of the spleen), significant differences in clinical responses or disease phenotype were not detectable between patients with and without Jak2 for CD8 + T-cells, respectively, by flow cytometry at day 7 p.i. as described before. 15 Cytokine-producing cells were identified by gating on live cells expressing CD45, CD3 and CD4 or CD45, CD3 and CD8 (n = 6 per group, *P o0.05). (b) Jak2 +/VF and Jak2 +/+ mice (n = 5 per group) were infected with 1 × 10 4 wild-type Lm and CFUs were determined in the spleens at day 7 p.i. (*Po0.05) according to a standard protocol. 15 (c) Absolute numbers of neutrophils (Ly6G high Ly6C high ) were determined by flow cytometry in the spleens and blood of Jak2 +/VF and Jak2 +/+ mice before and at day 7 p.i. (n = 6 per group; *Po 0.05). Histopathology analyses in the liver, spleen and lung of Jak2 +/VF and Jak2 +/+ mice were done by H&E staining at day 7 p.i. as described before.
2 (d) Absolute numbers (n = 6 per group) of extramedullary erythroblasts in the spleens of uninfected and Lm OVA-infected Jak2 +/VF and Jak2 +/+ mice were determined by flow cytometry at day 7 p.i. CD71 and TER119 were used to identify erythroblasts (*Po 0.05). (e) Serum erythropoietin levels of uninfected and Lm OVA-infected (day 7 p.i) Jak2
+/VF and Jak2 +/+ mice were determined in mouse serum using a commercial mouse erythropoietin ELISA (R&D Systems, Minneapolis, MN, USA; n = 6 per group; *Po0.05). (a − e) All mice were housed under pathogen-free conditions in the accredited Animal Research Facility at the Medical Faculty, OvGU, Magdeburg. We conducted all the experiments following approval by the Landesverwaltungsamt Saxony-Anhalt. Statistical significance was determined using the two-tailed Student t test and Po 0.05 was considered as significant.
but also additionally increased neutrophil numbers and extramedullary erythropoiesis, two hallmarks in patients with MPN.
14 Therefore, it is tempting to speculate on activation of T-cell clones by Jak2 V617F that it may-to a minor extent-contribute to the myeloproliferative phenotype through paracrine stimulation of myelopoiesis. Future prospective clinical trials will need to clarify to what extent Jak2 V617F -positive T-cell clones may enable improved control of specific infections while contributing to the chronic inflammatory phenotype upon challenge by pathogens and environmental antigens.
